Viking Therapeutics targets Phase 3 trials for VK2735 in Q2 2025 amid strong clinical progress
Viking plans to explore monthly dosing for ... for weight loss in the ongoing VENTURE trial for oral VK2735. Brian Lian ...
Yahoo Finance27d
Viking Therapeutics closer to bringing its Ozempic competitor to market
Viking Therapeutics (VKTX), the developer of ... anticipate will be significant commercial demand,” said Viking CEO Brian Lian in a press release. Despite the news, Viking’s stock fell over ...
Pharm Exec27d
Viking Therapeutics, CordenPharma Strike Multi-Year Deal to Commercialize VK2735 for Obesity, Metabolic Disorders
1 "We are excited to enter into this agreement with one of the world's leading CDMOs in the peptide space," said Brian Lian, PhD, CEO of Viking Therapeutics. "We have a long history of working with ...
Yahoo Finance12d
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
interest in participating in the Phase 2 VENTURE-Oral study was high and drove an efficient rate of enrollment," said Brian Lian, Ph.D., chief executive officer of Viking Therapeutics.
The Motley Fool Canada2mon
NASDAQ:VKTX (Viking Therapeutics)
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian ...